These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 20954857)

  • 1. Primary prevention using statins: to be or not to be?
    Breimer LH; Mikhailidis DP
    Curr Med Res Opin; 2010 Nov; 26(11):2701-6. PubMed ID: 20954857
    [No Abstract]   [Full Text] [Related]  

  • 2. Update on statins and other lipid-lowering drugs.
    Miller CA
    Geriatr Nurs; 2001; 22(5):276-7. PubMed ID: 11606910
    [No Abstract]   [Full Text] [Related]  

  • 3. Statins and all-cause mortality in high-risk primary prevention: a second look at the results.
    Chodick G; Shalev V
    Arch Intern Med; 2010 Dec; 170(22):2041-2; author reply 2043-4. PubMed ID: 21149767
    [No Abstract]   [Full Text] [Related]  

  • 4. Statins in primary prevention: uncertainty in women, elderly.
    Allen M;
    Am Fam Physician; 2006 Mar; 73(6):973-4; author reply 974. PubMed ID: 16570733
    [No Abstract]   [Full Text] [Related]  

  • 5. Are statins effective in high-risk primary prevention?
    Dentali F; Guasti L
    Arch Intern Med; 2010 Dec; 170(22):2042-3; author reply 2043-4. PubMed ID: 21149769
    [No Abstract]   [Full Text] [Related]  

  • 6. Is it appropriate to make statins available over the counter? Over-the-counter statins are worth considering in primary prevention of cardiovascular disease.
    Gotto AM
    Circulation; 2006 Sep; 114(12):1310-4; discussion 1314. PubMed ID: 16982952
    [No Abstract]   [Full Text] [Related]  

  • 7. The numbers are in: statins for the primary prevention of cardiovascular disease in women.
    Duvernoy CS; Blumenthal R
    Circulation; 2010 Mar; 121(9):1063-5. PubMed ID: 20176993
    [No Abstract]   [Full Text] [Related]  

  • 8. Primary prevention with over-the-counter statins: a cautionary tale.
    Davidoff F
    Clin Pharmacol Ther; 2005 Sep; 78(3):218-20. PubMed ID: 16153392
    [No Abstract]   [Full Text] [Related]  

  • 9. The editor's roundtable: the JUPITER trial--initial results and clinical implications.
    Ridker PM; Friedewald VE; Davidson MH; Willerson JT; Roberts WC
    Am J Cardiol; 2009 May; 103(10):1417-25. PubMed ID: 19427439
    [No Abstract]   [Full Text] [Related]  

  • 10. Statins reduce cardiovascular events in primary and secondary prevention trials without causing an increase in carcinoma.
    Aronow WS
    J Am Geriatr Soc; 2009 Oct; 57(10):1942-3; author reply 1943-4. PubMed ID: 19807799
    [No Abstract]   [Full Text] [Related]  

  • 11. Letter by Wells and Eisenberg regarding article, "Statins for the primary prevention of cardiovascular events in women with elevated high-sensitivity C-reactive protein or dyslipidemia: results from the Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) and meta-analysis of women from primary prevention trials".
    Wells MT; Eisenberg T
    Circulation; 2010 Dec; 122(23):e575; author reply e577. PubMed ID: 21135368
    [No Abstract]   [Full Text] [Related]  

  • 12. [Primary prevention of cardiovascular diseases with statins in women].
    Alici G; Karpuz V; Karpuz H
    Turk Kardiyol Dern Ars; 2009 Jun; 37(4):273-80. PubMed ID: 19717964
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The JUPITER Trial: responding to the critics.
    Ridker PM; Glynn RJ
    Am J Cardiol; 2010 Nov; 106(9):1351-6. PubMed ID: 21029837
    [No Abstract]   [Full Text] [Related]  

  • 14. Statins for the primary prevention of cardiovascular events in elderly patients: a picture from clinical practice without strong evidence from clinical trials.
    Trifirò G; Alacqua M; Corrao S; Tari M; Arcoraci V
    J Am Geriatr Soc; 2008 Jan; 56(1):175-7. PubMed ID: 18184214
    [No Abstract]   [Full Text] [Related]  

  • 15. Letter by Vos et al regarding article, "Statins for the primary prevention of cardiovascular events in women with elevated high-sensitivity C-reactive protein or dyslipidemia: results from the Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) and meta-analysis of women from primary prevention trials".
    Vos E; Rose CP; Biron P
    Circulation; 2010 Dec; 122(23):e576; author reply e577. PubMed ID: 21135369
    [No Abstract]   [Full Text] [Related]  

  • 16. The primary target. Taking aim at LDL levels to prevent cardiovascular disease.
    Mason CM
    Adv Nurse Pract; 2007 Dec; 15(12):55-8. PubMed ID: 20014676
    [No Abstract]   [Full Text] [Related]  

  • 17. Statins and hypertension.
    Cífková R; Nilsson PM
    J Hypertens; 2009 Mar; 27(3):662-5. PubMed ID: 19262236
    [No Abstract]   [Full Text] [Related]  

  • 18. Summaries of nursing care-related systematic reviews from the Cochrane library: statins for the primary prevention of cardiovascular disease.
    Li J; Zhou L
    J Cardiovasc Nurs; 2011; 26(4):288-9. PubMed ID: 21666420
    [No Abstract]   [Full Text] [Related]  

  • 19. Statins and all-cause mortality in high-risk primary prevention of patients with cardiovascular risk factors.
    Brugts JJ; Deckers JW
    Arch Intern Med; 2010 Dec; 170(22):2041; author reply 2043-4. PubMed ID: 21149768
    [No Abstract]   [Full Text] [Related]  

  • 20. Results of a Markov model analysis to assess the cost-effectiveness of statin therapy for the primary prevention of cardiovascular disease in Korea: the Korean Individual-Microsimulation Model for Cardiovascular Health Interventions.
    Kang HY; Ko SK; Liew D
    Clin Ther; 2009 Dec; 31(12):2919-30; discussion 2916-8. PubMed ID: 20110032
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.